Corpus ID: 19653942

Pharmacogenetics in the rheumatic diseases.

@article{Cronstein2004PharmacogeneticsIT,
  title={Pharmacogenetics in the rheumatic diseases.},
  author={B. Cronstein},
  journal={Annals of the rheumatic diseases},
  year={2004},
  volume={63 Suppl 2},
  pages={
          ii25-ii27
        }
}
  • B. Cronstein
  • Published 2004
  • Medicine
  • Annals of the rheumatic diseases
O ne of the promises of the human genome project is individualised pharmacological therapy. An individual’s genetic type would be determined, and the resulting diseases which the person was susceptible to would be determined. In addition, the drugs to which an individual would respond well would be enumerated, and the drugs which were more likely to be toxic could be established. At present we are just beginning to determine those associations which would help us tailor an individual’s… Expand
Personalized medicine in rheumatoid arthritis: hopes and challenges.
  • S. L. Bridges
  • Medicine
  • Bulletin of the NYU hospital for joint diseases
  • 2007
TLDR
The goal of identifying genetic, serum, and clinical factors that allow profiling of individual patients to predict optimal treatment regimens is a worthy pursuit which will hopefully improve clinical care of RA patients. Expand
Do genetic variations in the adenosine pathway affect patient response to methotrexate?
  • B. Cronstein
  • Medicine
  • Nature Clinical Practice Rheumatology
  • 2006
TLDR
An analysis of data from the results of the Behandelstrategieen voor Reumatoide Artritis (BeSt) study comparing the efficacy of four RA treatment regimens that include methotrexate found the following single-nucleotide polymorphisms (SNPs) were analyzed in the genes coding for adenosine mono phosphate deaminase (AMPD1, 34C>T): methionine synthase reductase. Expand
Causes of DMARD withdrawal following ADR within 6 months of initiation among Indian rheumatoid arthritis patients
TLDR
S Severity and symptomatology of disease, genetic pattern of patients, financial status, previous experience of the clinicians and patients, availability of drugs, patient expectations and compliance were the main factors that lead to a difference in pattern of therapy in patients compared to other population. Expand
Durability of treatment with methotrexate in Venezuelan patients with rheumatoid arthritis
TLDR
Venezuelan patients with RA have a probability of continuing treatment with oral MTX comparable to non-Hispanic patient populations, however, concomitant use of leflunomide may increase the risk of interruption of MTX treatment in this RA population. Expand
Impact of Environmental Factors on Efficacy of Glucocorticoids in Chinese Population with Systemic Lupus Erythematosus
TLDR
It is indicated that environmental factors, including salt intake, personality, experience with negative life events, and history of allergy, may play an important role in the efficacy of GCs in the Chinese population with SLE. Expand

References

SHOWING 1-10 OF 20 REFERENCES
Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses.
TLDR
Both single locus and haplotype analyses suggest that polymorphisms within the MTHFR gene are associated with both the efficacy and toxicity of MTX in rheumatoid arthritis patients. Expand
Relevance of thiopurine methyltransferase status in rheumatology patients receiving azathioprine.
TLDR
Analysis of recent data suggests that by optimizing the AZA dose on the basis of TPMT status testing, a reduction in drug-induced morbidity and cost savings can be made by avoiding hospitalization and rescue therapy for leucopenic events. Expand
Molecular action of methotrexate in inflammatory diseases
TLDR
In confirmation of this mechanism of action, recent studies in both animals and patients suggest that adenosine-receptor antagonists, among which is caffeine, reverse or prevent the anti-inflammatory effects of methotrexate. Expand
Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis.
TLDR
The results suggest that the genotyping for the TYMS polymorphisms may become a useful indicator in determining the appropriate dose of MTX in patients with RA. Expand
Efficacy of folinic acid in reducing methotrexate toxicity in juvenile idiopathic arthritis.
TLDR
Folinic acid supplementation resulted in a significant reduction in the most common side effects of MTX, without affecting the clinical efficacy of the drug. Expand
The use of folates concomitantly with low-dose pulse methotrexate.
  • J. Shiroky
  • Medicine
  • Rheumatic diseases clinics of North America
  • 1997
TLDR
Folinic acid supplementation should be considered prophylactically in those requiring methotrexate who are at increased risk of hepatic disease and claims that folic acid therapy is safer and more convenient than folinic acid seem unwarranted when one reviews the literature carefully. Expand
The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients.
TLDR
The C677T mutation is the first identified genetic risk factor for elevated alanine aminotransferase values duringMTX treatment in patients with RA and it is postulate that the incidence of clinically important elevation of liver enzyme levels during MTX treatment is mediated by homocysteine metabolism. Expand
The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis.
TLDR
It is concluded that a daily supplement of 1 mg of FA during low-dose MTX therapy (median dose 7.5 mg/week [16.4 mumoles]) is usefull in lessening toxicity without altering efficacy during the first 6 months of treatment. Expand
Folate supplementation during methotrexate treatment of patients with rheumatoid arthritis. An update and proposals for guidelines.
TLDR
An individually adjusted supply of folic acid rather than folinic acid is proposed for supplementation during methotrexate therapy of patients with rheumatoid arthritis, addressing both the timing of folate supplementation and the weekly folate-to-methotrexate ratio. Expand
The effects of daily intake of folic acid on the efficacy of methotrexate therapy in children with juvenile rheumatoid arthritis. A controlled study.
OBJECTIVE To determine the effect of 1 mg/day of folic acid on the efficacy of methotrexate (MTX) to control disease activity in children with juvenile rheumatoid arthritis (JRA). METHODSExpand
...
1
2
...